Related Experiment Video
Updated: Aug 7, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Aminoglycosides, imipenem, and aztreonam
1College of Pharmacy, University of Texas, Austin.
Abstract:
The aminoglycosides continue to be the cornerstone of antibiotic therapy for serious infections caused by gram-negative aerobic pathogens, even with the recent introduction of potent beta-lactams and the fluoroquinolones. Two of these newer agents are imipenem and aztreonam. Imipenem is the most expensive commercially available antibiotic, but it has the broadest range of activity, including most gram-negative and gram-positive, aerobic and anaerobic bacteria. Aztreonam, the first monobactam antibiotic to be released, has excellent activity against aerobic, gram-negative bacteria. It is not, however, simply a nonnephrotoxic replacement for aminoglycoside therapy. This article reviews the basic pharmacology and clinical utility of the aminoglycosides, imipenem, and aztreonam.
Insights
Aminoglycosides remain crucial for serious gram-negative infections. Newer antibiotics like imipenem and aztreonam offer broad-spectrum or specific gram-negative coverage, but do not fully replace aminoglycoside therapy.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Aminoglycosides are essential for treating serious gram-negative aerobic bacterial infections.
- Newer antibiotics, including beta-lactams and fluoroquinolones, have emerged but aminoglycosides remain a cornerstone therapy.
- Imipenem and aztreonam represent significant advancements in antibacterial agents.
Purpose of the Study:
- To review the pharmacology and clinical utility of aminoglycosides.
- To discuss the properties and applications of imipenem and aztreonam.
- To compare the efficacy and scope of these antibiotic classes.
Main Methods:
- Review of existing literature on aminoglycosides, imipenem, and aztreonam.
- Analysis of pharmacological profiles, including spectrum of activity and toxicity.
- Evaluation of clinical utility in treating serious bacterial infections.
Main Results:
- Aminoglycosides are vital for gram-negative aerobic pathogens.
- Imipenem exhibits the broadest spectrum of activity among the agents discussed.
- Aztreonam is effective against aerobic gram-negative bacteria but is not a direct substitute for aminoglycosides.
Conclusions:
- Aminoglycosides, imipenem, and aztreonam are important therapeutic options for serious bacterial infections.
- Each agent possesses unique pharmacological properties and clinical applications.
- Understanding their respective roles is crucial for effective antibiotic selection.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Acute Pyelonephritis II: Diagnostic Studies and Management
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Anthelminthic Agents

